Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Buys MAP To Chart Migraine Franchise Growth

This article was originally published in The Pink Sheet Daily

Executive Summary

Allergan partnered with MAP in 2011 for rights to commercialize Levadex for acute migraine in North America, but now will control 100% of the product’s revenue, creating a complementary product to Botox in chronic migraine. Levadex has an April 15 PDUFA date at FDA.

Advertisement

Related Content

Allergan Moves Into Busy CGRP Class By Buying Merck’s Oral Drugs
Allergan Manufacturing Headaches Continue For Semprana
Allergan Manufacturing Headaches Continue For Semprana
Allergan Bolsters Botox Business With Record-Setting Korean Deal
Allergan Bolsters Botox Business With Record-Setting Korean Deal
Allergan Bolsters Botox Biz With Medy-Tox Deal
Allergan’s Manufacturing Challenges Produce Second Levadex “Complete Response” Letter
Allergan Hopes To Shed Excess Fat As It Grows Other Franchises
A Headache For Map: Levadex Gets “Complete Response” Letter From FDA
Allergan And MAP Team Up On Inhalable Migraine Treatment

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074797

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel